This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

NICE recommendation

Ninlaro (ixazomib) is now
recommended by NICE via the CDF:

NINLARO (ixazomib) with lenalidomide and dexamethasone (Rd) is recommended for use within the Cancer Drugs Fund (CDF) as an option for treating multiple myeloma (MM) in adults if they have already had 2 or 3 previous lines of therapy and the conditions of the managed access agreement for ixazomib are followed7

7. NICE Final Appraisal Determination - Ixazomib, with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10043 Accessed December 2017

Close this message
NINLARO ixazomib capsules

Extended Efficacy.
Extended Possibilities.

NINLARO (ixazomib) + Rd significantly extends PFS vs Rd alone and offers
a manageable side effect profile with the convenience of an all-oral regimen1,2

NINLARO: the first and only oral proteasome inhibitor licensed in combination with lenalidomide and dexamethasone (Rd) for treatment of adult patients with multiple myeloma who have received at least 1 prior therapy2

Adding oral NINLARO to Rd extends PFS across a broad group of patients compared with Rd alone1,2

A long-term treatment approach in RRMM should address efficacy, tolerability and patient burden.3 However, long-term treatment in MM remains a challenge with a number of current therapeutic options.4 Adding oral NINLARO to Rd extends PFS across a broad group of patients irrespective of cytogenetic risk, compared with Rd alone.1 Find out more about how the NINLARO regimen may benefit patients with RRMM by exploring the case studies below.

David

Active 62 year old with early relapse post ASCT

  • Relapsed MM, R-ISS stage I, no adverse cytogenetics
  • Elevated serum M protein levels detected 11 months post ASCT (30 g/L)
  • Travels frequently for work and is the primary earner of income for his family
  • Needs to remain active for as long as possible to support and spend time with his family

Read more about how the NINLARO regimen may benefit patients like David

Sandra

Active 70 year old living alone in rural location

  • Relapsed MM, R-ISS stage II, no adverse cytogenetics, hypertension
  • Presents with new-onset back pain with limited movement and fatigue
  • Active volunteer for a local charity and lives alone 30 miles from tertiary centre
  • Needs a treatment regimen that is simple to integrate into her life and requires limited trips to and time in clinic

Read more about how the NINLARO regimen may benefit patients like Sandra

George

Retired 75 year old with cardiac and renal comorbidities

  • Relapsed MM, R-ISS stage III, no adverse cytogenetics, stable angina, hypertension, moderate renal impairment
  • Elevated serum M protein levels detected during routine clinic visit (25 g/L)
  • Retired and enjoys spending time with his family and friends
  • Needs a treatment regimen with a tolerability profile suitable for patients with his cardiac comorbidities and moderate renal impairment

Read more about how the NINLARO regimen may benefit patients like George

Mary

Active 69 year old with high‑risk cytogenetics

  • Relapsed MM, R-ISS stage III, high‑risk cytogenetics
  • Presents with recurrent back pain
  • Recently retired and has an active social life
  • Needs a treatment that has evidence of efficacy in high‑risk cytogenetics patients whilst maintaining a good quality of life

Read more about how the NINLARO regimen may benefit patients like Mary

Patient support

Takeda Oncology has developed a range of information and support tools designed for patients prescribed NINLARO

Click here to find out more about the support offered to NINLARO patients